title: Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis.
authors.affiliation: Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
authors.forename: Alexander
authors.initials: A
authors.lastname: Niessner
authors.affiliation: Department of Pharmacology, School of Medicine, University Complutense, Madrid, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Tamargo
authors.affiliation: Cardiology Division, Leiria Hospital Centre, Leiria, Portugal.
authors.forename: João
authors.initials: J
authors.lastname: Morais
authors.affiliation: Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
authors.forename: Lorenz
authors.initials: L
authors.lastname: Koller
authors.affiliation: Department of Cardiology, Isar Heart Center, Isar Klinikum, Munich, Germany.
authors.forename: Sven
authors.initials: S
authors.lastname: Wassmann
authors.affiliation: Department of Medicine, Regional Hospital West Jutland, Jutland, Denmark.
authors.forename: Steen Elkjær
authors.initials: SE
authors.lastname: Husted
authors.affiliation: Department of Health, Science and Technology, Aalborg University, Aalborg, Denmark.
authors.forename: Christian
authors.initials: C
authors.lastname: Torp-Pedersen
authors.affiliation: Copenhagen University Hospital (Holbaek Hospital), Holbæk, Denmark.|The Faculty of Medicine, Aalborg University, Aalborg, Denmark.
authors.forename: Keld
authors.initials: K
authors.lastname: Kjeldsen
authors.affiliation: Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-IIT, Haifa, Israel.
authors.forename: Basil S
authors.initials: BS
authors.lastname: Lewis
authors.affiliation: Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
authors.forename: Heinz
authors.initials: H
authors.lastname: Drexel
authors.affiliation: Cardiovascular and Cell Sciences Research Institute, St. George's, University of London, London, UK.
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Kaski
authors.affiliation: Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.|Faculty of Medicine, University of Oslo, Oslo, Norway.
authors.forename: Dan
authors.initials: D
authors.lastname: Atar
authors.affiliation: Department of Cardiovascular Science, University of Sheffield, Sheffield, UK.
authors.forename: Robert F
authors.initials: RF
authors.lastname: Storey
authors.affiliation: University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.|Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
authors.forename: Gregory Y H
authors.initials: GYH
authors.lastname: Lip
authors.affiliation: Radboud University Medical Centre, Nijmegen, The Netherlands.|Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.
authors.forename: Freek W A
authors.initials: FWA
authors.lastname: Verheugt
authors.affiliation: Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.|Faculty of Medicine, University of Oslo, Oslo, Norway.
authors.forename: Stefan
authors.initials: S
authors.lastname: Agewall
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage*; D000931:Antidotes / Q000627:therapeutic use*; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives; D032921:Consensus; D000069604:Dabigatran / Q000037:antagonists & inhibitors; D019317:Evidence-Based Medicine; D015951:Factor Xa / Q000008:administration & dosage; D005544:Forecasting; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D010879:Piperazines / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D012307:Risk Factors; D013927:Thrombosis / Q000188:drug therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000931:Antidotes; C580915:PRT064445; D010879:Piperazines; D011994:Recombinant Proteins; D014812:Vitamin K; D001120:Arginine; C000594745:idarucizumab; D015951:Factor Xa; D000069604:Dabigatran; C000593571:PER977